SCHEMBL24329679

SCHEMBL24329679

COc1ccc(-c2csc(NC(=O)c3ccn(C)n3)n2)cc1

nearest known ligand 0.62

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MEN1 O00255 7/20 0.62
▸ KMT2A Q03164 7/20 0.62
▸ ADORA3 P0DMS8 1/20 0.60
▸ GSTO1 P78417 1/20 0.58
▸ MAPT P10636 6/20 0.58
▸ ALDH1A1 P00352 6/20 0.58
▸ RAB9A P51151 5/20 0.58
▸ MAPK1 P28482 5/20 0.58
▸ LMNA P02545 5/20 0.58
▸ SMN1; SMN2 Q16637 5/20 0.58
▸ NPC1 O15118 3/20 0.58
▸ KDM4E B2RXH2 3/20 0.58
▸ NPSR1 Q6W5P4 2/20 0.58
▸ TP53 P04637 2/20 0.58
▸ RECQL P46063 1/20 0.58
▸ POLB P06746 1/20 0.58
▸ CASP3 P42574 1/20 0.58
▸ HTT P42858 1/20 0.58
▸ SENP8 Q96LD8 1/20 0.58
▸ SENP7 Q9BQF6 1/20 0.58

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL26658235 0.87 LMNA (0.59) MEN1KMT2AGSTO1MAPTALDH1A1
SCHEMBL26884180 0.86 KMT2A (0.61) MEN1KMT2AMAPTALDH1A1RAB9A
SCHEMBL26884172 0.86 MEN1 (0.54) MEN1KMT2AMAPTALDH1A1RAB9A
SCHEMBL24330744 0.86 PARP1 (0.57) MEN1KMT2AMAPTALDH1A1LMNA
SCHEMBL24329836 0.82 MAPT (0.50) MEN1KMT2AMAPTALDH1A1RAB9A
SCHEMBL24329676 0.81 MAPT (0.53) MEN1KMT2AADORA3MAPTALDH1A1
SCHEMBL12301134 0.81 ADORA3 (0.71) MEN1KMT2AADORA3GSTO1MAPT
SCHEMBL10922779 0.79 GSTO1 (0.74) MEN1KMT2AADORA3GSTO1MAPT
SCHEMBL10814398 0.79 MEN1 (0.83) MEN1KMT2AADORA3GSTO1MAPT
SCHEMBL26884174 0.78 HDAC3 (0.53) MEN1KMT2AMAPTALDH1A1RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230382903-A1 SMALL MOLECULE MODULATORS OF GP130 SIGNALING PATHWAYS, TOPICAL FORMULATIONS AND METHOD OF USE THEREOF CARTHRONIX INC (US) 2023-11-30 — — US disclosed
US-20230382903-A1 SMALL MOLECULE MODULATORS OF GP130 SIGNALING PATHWAYS, TOPICAL FORMULATIONS AND METHOD OF USE THEREOF CARTHRONIX INC (US) 2023-11-30 — — US disclosed
WO-2022082071-A1 SMALL MOLECULE MODULATORS OF GP130 SIGNALING PATHWAYS, TOPICAL FORMULATIONS AND METHOD OF US THEREOF CARTHRONIX, INC. (US) 2022-04-21 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230382903-A1 SMALL MOLECULE MODULATORS OF GP130 SIGNALING PATHWAYS, TOPICAL FORMULATIONS AND METHOD OF USE THEREOF STAT1, STAT3, STAT6 MEN1 4814/4885KMT2A 4379/4885ADORA3 2789/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback